2024
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian age
2021
Serial circulating tumor DNA samples from patients with metastatic breast cancer and BRCA1/2 mutations.
Collier K, Tallman D, Weber Z, Haynam M, Adams E, Jenison J, Asad S, Lustberg M, Cherian M, Ramaswamy B, Sardesai S, Williams N, Wesolowski R, VanDeusen J, Gatti-Mays M, Pariser A, Mortazavi A, Stover D. Serial circulating tumor DNA samples from patients with metastatic breast cancer and BRCA1/2 mutations. Journal Of Clinical Oncology 2021, 39: 1025-1025. DOI: 10.1200/jco.2021.39.15_suppl.1025.Peer-Reviewed Original ResearchMetastatic breast cancerTargeted panel sequencingPlatinum chemotherapySomatic copy number alterationsPARP inhibitorsBreast cancerPlasma samplesSerial ctDNA samplesHormone receptor statusNon-invasive evaluationPass whole genome sequencingDNA damage repair genesLast time pointTumor DNA samplesReceptor statusHR statusControl cohortLast timepointBRCA1/2 mutationsSomatic BRCA1Blood samplesCancer-related genesCtDNA samplesSerial samplesTumor fraction